captopril has been researched along with Experimental Hepatoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diepart, C; Gallez, B; Grégoire, V; Jordan, BF; Karroum, O; Magat, J; Peeterbroeck, J | 1 |
| Ager, EI; Angus, PW; Christophi, C; Herath, CB; Neo, JH; Zhu, J | 1 |
| Al-Ismaeel, H; Al-Rikabi, AC; Al-Shabanah, OA; Mansour, MA | 1 |
| Ager, EI; Chan, J; Chong, WW; Christophi, C; Neo, JH; Wen, SW | 1 |
4 other study(ies) available for captopril and Experimental Hepatoma
| Article | Year |
|---|---|
Captopril and S-nitrosocaptopril as potent radiosensitizers: Comparative study and underlying mechanisms.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Hemodynamics; Liver Neoplasms, Experimental; Male; Mice; Neoplasm Transplantation; Nitric Oxide; Oxygen Consumption; Radiation Tolerance; Vasodilator Agents | 2010 |
Changes in the renin angiotensin system during the development of colorectal cancer liver metastases.
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Animals; Captopril; Colorectal Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred CBA; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin; Renin-Angiotensin System | 2010 |
Comparison of angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockade for the prevention of premalignant changes in the liver.
Topics: alpha-Fetoproteins; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticarcinogenic Agents; Captopril; Carcinoembryonic Antigen; Endostatins; Enzyme-Linked Immunosorbent Assay; Fibroblast Growth Factors; Hydroxyproline; Liver; Liver Neoplasms, Experimental; Losartan; Male; Matrix Metalloproteinase 2; Metallothionein; Perindopril; Precancerous Conditions; Rats; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2011 |
Altered efficacy of AT1R-targeted treatment after spontaneous cancer cell-AT1R upregulation.
Topics: Adenocarcinoma; Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Biomarkers, Tumor; Biphenyl Compounds; Captopril; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Irbesartan; Liver Neoplasms, Experimental; Mice; Mice, Inbred CBA; Molecular Targeted Therapy; Neoplasm Proteins; Neovascularization, Pathologic; Oligopeptides; Peptide Fragments; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Tetrazoles; Tumor Burden; Up-Regulation; Vascular Endothelial Growth Factor A | 2011 |